2024-05-09 11:39:11 ET
Intellia Therapeutics, Inc. (NTLA)
Q1 2024 Results Conference Call
May 9, 2024 08:00 AM ET
Company Participants
Ian Karp - Senior Vice President of Investor Relations and Corporate Communications
John Leonard - Chief Executive Officer
David Lebwohl - Chief Medical Officer
Laura Sepp-Lorenzino - Chief Scientific Officer
Glenn Goddard - Chief Financial Officer
Conference Call Participants
Yanan Zhu - Wells Fargo Securities
Maury Raycroft - Jefferies
Troy Langford - TD Cowen
Luca Issi - RBC Capital
Kostas Biliouris - BMO
Benazir Ali - Stifel
Brian Cheng - JPMorgan
Mary Kate Davis - Bank of America
Rick Bienkowski - Cantor
Silvan Tuerkcan - JMP Securities
Timor Vanicus - Raymond James Financial
William Pickering - Bernstein
Presentation
Operator
Good morning, and welcome to Intellia Therapeutics’ First Quarter 2024 Financial Results Conference Call. My name is Drew, and I will be your conference operator today. Following formal remarks, we will open the call up for a question-and-answer session. This conference is being recorded at the company's request and will be available on the company's website following the end of the call. As a reminder, all participants are currently in listen-only mode. [Operator Instructions]
I will now turn the conference over to Ian Karp, Senior Vice President of Investor Relations and Corporate Communications at Intellia. Please proceed.
Ian Karp
Thank you, operator, and good morning, everyone. Welcome to Intellia Therapeutics first quarter 2024 earnings call. Earlier this morning, Intellia issued a press release outlining the company's progress this quarter, as well as topics for discussion on today's call. This release can be found on the Investors and Media section of Intellia's website at intelliatx.com. This call is being broadcast live and a replay will be archived on the company's website.
At this time, I'd like to take a minute to remind listeners that during this call, Intellia Management may make certain forward-looking statements and ask that you refer to our SEC filings available at sec.gov for discussion of potential risks and uncertainties. All information presented on this call is current as of today, and Intellia undertakes no duty to update this information unless required by law.
Joining me from Intellia are John Leonard, Chief Executive Officer; David Lebwohl, Chief Medical Officer; Laura Sepp-Lorenzino, Chief Scientific Officer; and Glenn Goddard, Chief Financial Officer. John will begin with an overview of recent business highlights. David will provide an update on our clinical pipeline progress, Laura will review our R&D updates, and Glenn will review our financials before we open up the call for questions....
Read the full article on Seeking Alpha
For further details see:
Intellia Therapeutics, Inc. (NTLA) Q1 2024 Earnings Call Transcript